NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis $0.25 +0.01 (+3.55%) Closing price 07/3/2025 03:42 PM EasternExtended Trading$0.25 0.00 (0.00%) As of 07/3/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Adaptimmune Therapeutics Stock (NASDAQ:ADAP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADAP alerts:Sign Up Key Stats Today's Range$0.24▼$0.2550-Day Range$0.23▼$0.3052-Week Range$0.20▼$1.48Volume459,962 shsAverage Volume1.66 million shsMarket Capitalization$66.53 millionP/E RatioN/ADividend YieldN/APrice Target$1.35Consensus RatingHold Company Overview Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Read More Adaptimmune Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreADAP MarketRank™: Adaptimmune Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 620th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAdaptimmune Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Adaptimmune Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 5.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adaptimmune Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.97% of the float of Adaptimmune Therapeutics has been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 14.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.97% of the float of Adaptimmune Therapeutics has been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adaptimmune Therapeutics has recently decreased by 14.61%, indicating that investor sentiment is improving significantly. News and Social Media1.4 / 5News Sentiment0.45 News SentimentAdaptimmune Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Adaptimmune Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ADAP on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.74% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.Read more about Adaptimmune Therapeutics' insider trading history. Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADAP Stock News HeadlinesAdaptimmune Therapeutics PLC (NASDAQ:ADAP) Receives $1.35 Consensus Price Target from AnalystsJuly 2, 2025 | americanbankingnews.comMizuho Downgrades Adaptimmune Therapeutics (NASDAQ:ADAP) to NeutralJune 28, 2025 | americanbankingnews.comCold War Discovery Could Unlock $100 Trillion in WealthObscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered. | Brownstone Research (Ad)Mizuho Downgrades Adaptimmune Therapeutics plc - Depositary Receipt () (ADAP)June 27, 2025 | msn.comMizuho downgrades Adaptimmune stock on solvency concernsJune 26, 2025 | investing.comAdaptimmune Therapeutics PLC: Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025June 4, 2025 | finanznachrichten.deAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2025 Earnings Call TranscriptMay 14, 2025 | insidermonkey.comAdaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ...May 14, 2025 | finance.yahoo.comSee More Headlines ADAP Stock Analysis - Frequently Asked Questions How have ADAP shares performed this year? Adaptimmune Therapeutics' stock was trading at $0.5387 at the beginning of 2025. Since then, ADAP stock has decreased by 53.4% and is now trading at $0.2510. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics PLC (NASDAQ:ADAP) announced its quarterly earnings data on Tuesday, May, 13th. The biotechnology company reported ($0.18) EPS for the quarter, meeting analysts' consensus estimates of ($0.18). The biotechnology company earned $7.29 million during the quarter, compared to the consensus estimate of $6.55 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 163.73% and a negative net margin of 38.91%. Read the conference call transcript. When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), American Water Works (AWK), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/13/2025Today7/06/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAP CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees490Year FoundedN/APrice Target and Rating Average Stock Price Target$1.35 High Stock Price Target$3.00 Low Stock Price Target$0.46 Potential Upside/Downside+438.5%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.81 million Net Margins-38.91% Pretax Margin-36.89% Return on Equity-163.73% Return on Assets-23.65% Debt Debt-to-Equity Ratio4.24 Current Ratio2.02 Quick Ratio1.79 Sales & Book Value Annual Sales$179.64 million Price / Sales0.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book5.02Miscellaneous Outstanding Shares265,052,000Free Float231,284,000Market Cap$66.53 million OptionableOptionable Beta2.18 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:ADAP) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADAP Stock Alerts